Provided by Tiger Fintech (Singapore) Pte. Ltd.

Foghorn Therapeutics Inc.

5.13
+0.18003.64%
Post-market: 5.190.0600+1.17%13:04 EDT
Volume:80.45K
Turnover:410.35K
Market Cap:285.95M
PE:-3.83
High:5.18
Open:5.02
Low:4.96
Close:4.95
Loading ...

Foghorn Therapeutics Signs New Lease Agreement

TIPRANKS
·
02 Jul

Foghorn Therapeutics Signs Major Lease Agreement for New Watertown Headquarters

Reuters
·
02 Jul

Foghorn Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
18 Jun

Morgan Stanley Reaffirms Their Hold Rating on Foghorn Therapeutics (FHTX)

TIPRANKS
·
12 Jun

Foghorn Therapeutics Inc. to Present at Goldman Sachs 46th Annual Global Healthcare Conference 2025

Reuters
·
22 May

Promising Advancements and Strategic Collaborations Drive Buy Rating for Foghorn Therapeutics

TIPRANKS
·
15 May

Foghorn Therapeutics Inc. reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Foghorn Therapeutics Reports Strong Cash Position with $220.6 Million, Ensures Cash Runway into 2027; No Specific Sales or EPS Data Disclosed

Reuters
·
14 May

BRIEF-Foghorn Therapeutics Q1 EPS USD -0.3

Reuters
·
14 May

Foghorn Therapeutics Q1 Net Income USD -18.834 Million

THOMSON REUTERS
·
14 May

Foghorn Therapeutics: Robust Balance Sheet, Cash Runway Into 2027; to Deliver High-Impact Therapeutics in 2025 and Beyond

THOMSON REUTERS
·
14 May

Foghorn Therapeutics Q1 EPS USD -0.3

THOMSON REUTERS
·
14 May

Press Release: Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

Dow Jones
·
14 May

North American Morning Briefing: Stock Futures Surge on China Deal

Dow Jones
·
12 May

North American Morning Briefing: Stock Futures Down As Oil Plunges

Dow Jones
·
05 May

Foghorn Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Neil Gallagher

Reuters
·
03 May

Foghorn Therapeutics Inc. expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
02 May

Foghorn Therapeutics Inc. Appoints Neil Gallagher and Stuart Duty to Board of Directors to Strengthen Strategic Leadership

Reuters
·
01 May

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to Its Board of Directors

THOMSON REUTERS
·
01 May

Press Release: Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

Dow Jones
·
01 May